VIDEO: Data on drug combination impacts standard of care in refractory colorectal cancer
Click Here to Manage Email Alerts
Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed the mature phase 3 data on the addition of bevacizumab to trifluridine/tipiracil in refractory colorectal cancer in a video interview with Healio.
The data was presented at ASCO Gastrointestinal Cancers Symposium. Schlechter said he thinks that this data “confirms” the practice of using trifluridine/tipiracil (Lonsurf; Taiho Oncology, Servier) with bevacizumab (Avastin, Genentech) in the U.S.
“I think this is practice-changing in the E.U., the U.K. and elsewhere in the world where that combination is not yet formally approved,” he said. “I think that slightly modifies the standard of care for refractory colorectal cancer and I think that [bevacizumab] becomes sort of an official part of that standard.”
Reference:
- Tabernero J, et al. Abstract 4. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 19-21, 2023; San Francisco.
Collapse
Healio Interview
Click Here to Manage Email Alerts